Leerink Partners analyst Marc Goodman has maintained their bullish stance on JAZZ stock, giving a Buy rating on June 11.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Marc Goodman has given his Buy rating due to a combination of factors surrounding Jazz Pharmaceuticals’ recent developments. The positive data from the Zepzelca and Tecentriq combination for 1L maintenance therapy in extensive-stage small cell lung cancer (ES-SCLC) is a significant factor. This combination has shown a survival benefit in the Phase 3 IMforte trial, which is promising and has led to a priority review with a PDUFA date set for October 7. This development is seen as an encouraging step towards approval for the new indication.
Moreover, the IMforte trial is noteworthy as it is the first to meet the primary endpoints of progression-free survival (PFS) and overall survival (OS) in the 1L maintenance setting for ES-SCLC. This success positions the combination as a potential new standard of care for patients who have not progressed after 1L induction therapy. While there are concerns about the loss of exclusivity towards the end of the decade, the upcoming Zani data in gastric cancer is expected to be positive and is anticipated to be a key driver for the stock, reinforcing the Buy rating.
Goodman covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Aldeyra Therapeutics, and Relmada Therapeutics. According to TipRanks, Goodman has an average return of 3.6% and a 46.23% success rate on recommended stocks.
In another report released on June 11, TD Cowen also maintained a Buy rating on the stock with a $205.00 price target.